We believe that the ability of clinicians to safely, rapidly and precisely deliver life-extending therapies in aerosol form directly to the lungs will someday transform pulmonary critical care in human and veterinary medicine.
Since our devices were first introduced, researchers around the world have demonstrated the significant clinical relevance of Penn-Century’s intratracheal aerosol technology. The sheer number and breadth of peer-reviewed studies and drug patents citing our devices is unrivaled. Together they offer compelling evidence of what is possible.
We see this potential clearly. If you do as well, we welcome you to contact us if you have had proven success in taking a disruptive technology into clinical use and access to appropriate funding resources.